John Szilagyi (left) is a Principal Scientist at Bristol Myers Squibb (NJ, USA), working in nonclinical development and investigative toxicology, with a focus on the development of models to study ...
Advanced 3D cell models recreate the complexity of human tissues, enabling researchers to examine tumor progression, probe neurological disorders, and assess therapeutic candidates. By capturing the ...
Traditionally, scientists have used 2D cell cultures as in vitro models in drug screening studies due to their simplicity and scalability. However, 2D cell models do not recapitulate the complexity of ...
3D bio-printed liver model and high-content imaging for evaluating the toxicity effects of compounds
The effectiveness of non-clinical drug safety predictions is enhanced by the adoption of three-dimensional (3D) cellular models. 3D bioprinting enables the generation of complex models with spatial ...
A new in-plate, zero-disruption design enables reproducible organoid culture, downstream processing, and high-resolution imaging in a single 3D cell culture plate MONMOUTH JUNCTION, N.J., Feb. 9, 2026 ...
Most potential oncology drugs fail during the drug development pipeline, even when there has been promising data for their efficacy during the in vitro stage. This makes it vital to identify in vitro ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results